Pyxis Oncology, Inc.

Equities

PYXS

US7473241013

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
3.74 ^USD	-1.84%		-6.50%	+107.78%

May. 14	Earnings Flash (PYXS) PYXIS ONCOLOGY Posts Q1 Revenue $16.1M	MT
May. 14	Pyxis Oncology, Inc. Appoints Stephen Worsley as its Senior Vice President	CI

Pyxis Oncology : RBC Capital Markets Global Healthcare Conference

May 15, 2024 at 07:01 am EDT

May 14, 2024 at 3:05 PM EDT

Listen to webcast

Attachments

Original Link
Permalink

Disclaimer

Pyxis Oncology Inc. published this content on 14 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 May 2024 11:00:35 UTC.

Latest news about Pyxis Oncology, Inc.

Earnings Flash (PYXS) PYXIS ONCOLOGY Posts Q1 Revenue $16.1M	May. 14	MT
Pyxis Oncology, Inc. Appoints Stephen Worsley as its Senior Vice President	May. 14	CI
H.C. Wainwright Adjusts Price Target on Pyxis Oncology to $7 From $4, Maintains Buy Rating	Mar. 22	MT
Health Care Up on Drug Sales Optimism -- Health Care Roundup	Mar. 21	DJ
Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Pyxis Oncology, Inc. Appoints Santhosh Palani to Its Board of Directors	Mar. 13	CI
Pyxis Oncology Announces Private Placement of Shares, Pre-Funded Warrants to Raise $50 Million	Feb. 27	MT
Pyxis Oncology, Inc. announced that it expects to receive $49.999989 million in funding from Blue Owl Healthcare Opportunities, StemPoint Capital LP, Deep Track Capital, LP, Laurion Capital Management LP, Ridgeback Capital Management LLC and another investors	Feb. 25	CI
BTIG Initiates Pyxis Oncology With Buy Rating, $8 Price Target	Feb. 09	MT
Leerink Partners Initiates Coverage on Pyxis Oncology with Outperform Rating, $12 Price Target	Jan. 23	MT
HC Wainwright Starts Pyxis Oncology With Buy Rating, $4 Price Target	Nov. 30	MT
Pyxis Oncology, Inc. Appoints Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer	Nov. 28	CI
Pyxis Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Pyxis Oncology Shares Fall After CEO Sells Stock	23-09-19	MT
RBC Initiates Pyxis Oncology at Outperform With Speculative Risk, Sets Price Target at $7, Sees 'Favorable' Risk/Reward	23-09-05	MT
Pyxis Oncology Completes Acquisition of Apexigen	23-08-23	MT
Pyxis Oncology, Inc. Appoints Jakob Dupont as Independent Director to the Board of Directors	23-08-23	CI
Pyxis Oncology, Inc. completed the acquisition of Apexigen, Inc. from entities associated with Pfizer Inc., Lincoln Park Capital, LLC, managed by Laurion Capital Management LP, Bayer World Investments B.V. and others.	23-08-22	CI
Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Pyxis Oncology Doses First Subject in Phase 1 Trial of Immunotherapy Antibody Candidate	23-05-30	MT
Pyxis Oncology, Inc. Advances Pyx-106 and PYX-201 Clinical Programs	23-05-30	CI
Wall Street Set to Open Lower as Investors Await Progress on Debt-Ceiling Talks Ahead of Fed Minutes Release	23-05-24	MT
Sector Update: Health Care Stocks Mixed Premarket Wednesday	23-05-24	MT
Sector Update: Health Care	23-05-24	MT
Transcript : Apexigen, Inc., Pyxis Oncology, Inc. - M&A Call	23-05-24

Chart Pyxis Oncology, Inc.

Duration

Period

More charts

Company Profile

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Jefferies Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.74 USD

Average target price

8.8 USD

Spread / Average Target

+135.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PYXIS ONCOLOGY, INC.	+107.78%	220M
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	115B
REGENERON PHARMACEUTICALS, INC.	+10.80%	105B
BIONTECH SE	-10.84%	22.71B
ARGENX SE	-1.63%	21.83B
GENMAB A/S	-10.70%	18.18B
WUXI APPTEC CO., LTD.	-41.92%	16.52B
BEIGENE, LTD.	-15.11%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.14B
SAREPTA THERAPEUTICS, INC.	+17.53%	10.71B

Bio Therapeutic Drugs